CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
  NCT07078604 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
  NCT05242965 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
  NCT07112053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine?

3 recruiting trials across 8 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.